MiNK Therapeutics AgenT-797 Phase II Results
Analysis based on 7 articles · First reported Apr 17, 2026 · Last updated Apr 17, 2026
The positive Phase II trial results for AgenT-797 are likely to boost investor confidence in MiNK Therapeutics, potentially leading to an increase in its stock price. This development could also attract potential partners for further development, impacting the broader biotechnology and pharmaceutical markets.
MiNK Therapeutics announced positive data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, evaluating agenT-797 in combination with botensilimab, balstilimab, ramucirumab, and paclitaxel for advanced PD-1 refractory gastroesophageal adenocarcinoma. The study showed a 77% disease control rate and long-term survival beyond 20 months in a subset of patients, with an induction strategy linked to improved progression-free survival and overall survival. While the primary endpoint of overall response rate was not met, the durability of survival and evidence of immune activation support further study. The data was presented at the American Association for Cancer Research Annual Meeting.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard